Psychiatry · Coral Gables, FL
NPI
1427048115
Since 2005
Specialty
Psychiatry
Code 2084P0800X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
401 Coral Way, #208a
Coral Gables, FL, 33134
Phone (786) 564-9844
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$884K
1,769 prescriptions
Company payments, 2025
$813K
From 20 companies
Medicare prescription drug claims, 2024
In 2024, the drug Ilan Melnick prescribed most often to Medicare patients was Olanzapine, with 107 prescriptions and refills. In total Ilan Melnick wrote 1,769 Medicare prescriptions that cost $884K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-01-04.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Olanzapine Generic | 107 | 109 | Under 11 | $2,971 |
| Benztropine Mesylate Generic | 84 | 85 | Under 11 | $1,275 |
| Divalproex Sodium Er Divalproex Sodium | 76 | 78 | Under 11 | $8,281 |
| Clonazepam Generic | 74 | 89 | 11 | $603 |
| Trazodone Hcl Generic | 69 | 88 | 12 | $960 |
| Quetiapine Fumarate Generic | 68 | 116 | Under 11 | $1,531 |
| Risperidone Generic | 66 | 75 | Under 11 | $1,273 |
| Trintellix Vortioxetine Hydrobromide | 58 | 59 | Under 11 | $26K |
| Uzedy Risperidone | 57 | 61 | Under 11 | $192K |
| Lorazepam Generic | 51 | 52 | Under 11 | $505 |
| Olanzapine Odt Olanzapine | 48 | 48 | Under 11 | $10K |
| Quetiapine Fumarate Er Quetiapine Fumarate | 47 | 48 | Under 11 | $9,743 |
| Chlorpromazine Hcl Generic | 47 | 48 | Under 11 | $5,190 |
| Citalopram Hbr Citalopram Hydrobromide | 41 | 49 | Under 11 | $336 |
| Gabapentin Generic | 39 | 54 | Under 11 | $670 |
Brand drugs: 354 claims; generic drugs: 1,415 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ilan Melnick $813K ($813K in general payments such as food, travel and fees) from 20 companies. The largest payer was Neurocrine BioSciences, Inc. with $160K.
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. NBIX | 145 | $160K |
| E.R. Squibb & Sons, L.L.C. BMY | 116 | $142K |
| Otsuka America Pharmaceutical, Inc. 4578.T | 133 | $140K |
| Teva Pharmaceuticals USA, Inc. TEVA | 94 | $120K |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 70 | $89K |
| Axsome Therapeutics, Inc. AXSM | 80 | $71K |
| Abbvie Inc. ABBV | 24 | $22K |
| H. Lundbeck A S HLUN-A.CO | 13 | $21K |
| Alkermes, Inc. ALKS | 23 | $16K |
| Boehringer Ingelheim International GmbH | 1 | $12K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.